Efficacy and safety of LM-108, an anti-CCR8 monoclonal antibody, …
May 29, 2024 · LM-108 is a novel Fc-optimized, anti-CCR8 monoclonal antibody that selectively depletes tumor-infiltrating Tregs. Here we report a pooled analysis of results from 3 phase 1/2 …
Therapeutic depletion of CCR8 - PubMed
Collectively, our findings highlight the efficacy and safety of targeting CCR8 for the depletion of tumor-promoting ti-Tregs in combination with anti-PD-1 therapy.
- Author: Helena Van Damme, Bruno Dombrecht, Máté Kiss, Heleen Roose, Elizabeth Allen, Eva Van Overmeire, Dali...
- Publish Year: 2021
S-531011, a Novel Anti-Human CCR8 Antibody, Induces Potent …
Sep 5, 2023 · We observed that S-531011 reduced tumor-infiltrating CCR8+ Tregs and induced potent antitumor activity in a tumor-bearing human-CCR8 knock-in mouse model. Moreover, …
- Studies of CCR8 PD-1
The impact of CCR8+ regulatory T cells on cytotoxic T cell ... - Nature
Mar 30, 2022 · Recent studies identified selective CCR8 expression on tumor-infiltrating Tregs; CCR8+ Tregs have been indicated as a possible new target of cancer immunotherapy. Here, …
A single-cell atlas reveals immune heterogeneity in anti-PD-1 …
Mar 26, 2025 · It has been previously reported that CCR8 + Tregs suppress the proliferation of CD8 + T cells. 46, 47 Preclinical models have shown that Treg-depleting anti-CCR8 agents …
CCR8: a promising therapeutic target against tumor-infiltrating ...
Feb 1, 2025 · CC chemokine receptor (CCR)8 has emerged as a promising therapeutic target against TI-Treg cells for its predominant expression on effector TI-Treg cells and minimal …
- People also ask
Differential expression of CCR8 in tumors versus normal tissue …
Nov 4, 2022 · Targeting CCR8 in mouse tumor models results in robust anti-tumor efficacy, which is dependent on Treg depleting activity, and synergizes with PD-1 inhibition to promote anti …
S-531011, a Novel Anti-Human CCR8 Antibody, …
To generate an anti-human CCR8 antibody suitable for cancer immunotherapy, we screened monoclonal anti-CCR8 IgG1 antibodies and found a novel anti-human CCR8 antibody S-531011 that showed high binding affinity to CCR8, …
Abstract 6694: Highly selective anti-CCR8 antibody …
Aug 15, 2020 · CCR8+ Treg depletion led to robust antitumor activity alone and in combination with anti–PD-1 in mouse tumor models. These results support further clinical evaluation of CCR8 depletion in combination with immune checkpoint …
CCR8 antagonist suppresses liver cancer progression via turning …
Apr 4, 2025 · In the muscle-invasive bladder cancer model, CCR8 blockade destabilizes intratumoral Tregs into a fragile phenotype, associated with reactivation of antitumor immunity …
Related searches for CCR8 PD-1
